Paolo Rigano

Improving survival with deferiprone treatment in patients with thalassemia major: A prospective multicenter randomised clinical trial under the auspices of the Italian Society for Thalassemia and Hemoglobinopathies

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · Blood Cells Molecules and Diseases · 2009 · 96 citations

Hematology, Clinical Trials, Italian Society +5

Long‐term sequential deferiprone–deferoxamine <i>versus</i> deferiprone alone for thalassaemia major patients: a randomized clinical trial

Aurelio Maggio, Angela Vitrano, Marcello Capra et al. · British Journal of Haematology · 2009 · 69 citations

Drug Safety, Therapeutic Drug Monitoring, Randomized Clinical Trial +11

Real-life experience with hydroxyurea in sickle cell disease: A multicenter study in a cohort of patients with heterogeneous descent

Paolo Rigano, Lucia De Franceschi, Laura Sainati et al. · Blood Cells Molecules and Diseases · 2017 · 55 citations · Full text

Translational Medicine, Sickle Cell Disease, Hematology +4

Treatment of hepatitis C virus infection with direct‐acting antiviral drugs is safe and effective in patients with hemoglobinopathies

Raffaella Origa, Maria Laura Ponti, Aldo Filosa et al. · American Journal of Hematology · 2017 · 45 citations · Full text

Pathology, Antiviral Drug, Cirrhosis +23

Desensitization to hydroxycarbamide following long‐term treatment of thalassaemia intermedia as observed <i>in vivo</i> and in primary erythroid cultures from treated patients

Paolo Rigano, A. Pecoraro, Roberta Calzolari et al. · British Journal of Haematology · 2010 · 43 citations · Full text